文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

北美结核患者的利奈唑胺给药与药代动力学

Linezolid Dosing and Pharmacokinetics in North American Patients With Tuberculosis.
PubMed 文献 · Clin Infect Dis · 2025-01-01

本研究通过国际治疗药物监测(TDM)服务,分析2019年1月至2023年12月北美500例结核患者的1604份利奈唑胺样本。约三分之一谷浓度样本>2 μg/mL,600 mg日剂量组中43.2%谷浓度>2 μg/mL;600份峰浓度样本中44%超出典型范围,其中89%<12 μg/mL。TDM可识别浓度超出目标范围的患者,帮助临床医生调整剂量以改善结局。

要点

  • 500例结核患者共817次TDM,232份(34.6%)谷浓度>2 μg/mL。
  • 600 mg日剂量组谷浓度样本中43.2%>2 μg/mL。
  • 600份峰浓度样本中44%超出典型范围,其中89%<12 μg/mL。

核心结论

  • 约三分之一谷浓度样本和超过40%服用推荐剂量者的谷浓度>2 μg/mL,超过40%峰浓度超出典型范围且其中89%<12 μg/mL。
  • TDM可识别血清利奈唑胺浓度超出目标范围的患者,使临床医生能够进行适当的剂量调整以改善结局。

研究设计与样本

  • 研究分析来自北美各地的利奈唑胺给药后谷浓度、2小时和6小时临床样本,由佛罗里达大学传染病药代动力学实验室采用液相色谱-串联质谱法测定总血清浓度。
  • 2019年1月至2023年12月期间,共分析来自500例患者的1604份利奈唑胺样本和817次独立TDM。
  • TDM测量结果与典型利奈唑胺浓度比较,包括谷浓度<2 μg/mL和峰浓度12至26 μg/mL。

主要发现

  • 670份样本测量了谷浓度,中位数1.19(范围0.00-20.06)μg/mL,其中232份(34.6%)谷浓度>2 μg/mL。
  • 利奈唑胺600 mg每日给药组的谷浓度样本中,43.2%>2 μg/mL。
  • 600份峰浓度样本中264份(44%)超出典型范围,其中大多数(89%)低于治疗水平,<12 μg/mL。

关键数值与推荐

  • 谷浓度目标值<2 μg/mL,峰浓度典型范围为12至26 μg/mL。

临床怎么用

  • TDM可用于识别血清利奈唑胺浓度超出目标范围的患者,使临床医生能够进行适当的剂量调整以改善结局。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Linezolid is recommended in treatment regimens for rifampin- or multidrug-resistant tuberculosis (TB). However, considerable pharmacokinetic variability exists, and long-term use is limited by adverse effects. This study evaluates the pharmacokinetics of linezolid in patients with TB from an international therapeutic drug monitoring (TDM) service. METHODS: Linezolid trough, 2-hour, and 6-hour postdose clinical samples from across North America were tested by the University of Florida Infectious Disease Pharmacokinetics Laboratory. Total serum concentrations were measured using liquid chromatography-tandem mass spectrometry. TDM was performed, and measurements were compared to typical linezolid concentrations including a trough value of <2 μg/mL and peak value between 12 and 26 μg/mL. RESULTS: From January 2019 to December 2023, 1604 linezolid samples from 500 patients and 817 unique TDM occasions were analyzed. Trough concentrations were measured on 670 samples (median, 1.19 [range, 0.00-20.06] μg/mL), and 232 troughs (34.6%) were >2 μg/mL. Among trough samples from linezolid dosing of 600 mg daily, 43.2% were >2 μg/mL. Of 600 peak samples, 264 (44%) were outside the typical range, most (89%) being subtherapeutic at <12 μg/mL. CONCLUSIONS: High serum linezolid trough concentrations were measured in approximately one-third of samples and in >40% of those taking the recommended dose. More than 40% of peak concentrations were outside typical range, of which 89% were <12 μg/mL. This study demonstrates that TDM can be used to identify patients with serum linezolid concentrations outside of targeted ranges, allowing clinicians to make appropriate dose adjustments to improve outcomes.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Maranchick NF, Peloquin CA, Haley CA, et al. Linezolid Dosing and Pharmacokinetics in North American Patients With Tuberculosis. Clin Infect Dis. 2025. PMID: 39834217. doi:10.1093/cid/ciaf027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。